US 12,465,640 B2
Methods and compositions for treating inflammatory and autoimmune conditions with ECM-affinity peptides linked to anti-inflammatory agents
Jeffrey A. Hubbell, Chicago, IL (US); Kiyomitsu Katsumata, Chicago, IL (US); Ako Ishihara, Chicago, IL (US); Jun Ishihara, Chicago, IL (US); and Aslan Mansurov, Chicago, IL (US)
Assigned to The University of Chicago, Chicago, IL (US)
Appl. No. 17/310,802
Filed by The University of Chicago, Chicago, IL (US)
PCT Filed Feb. 25, 2020, PCT No. PCT/US2020/019668
§ 371(c)(1), (2) Date Aug. 25, 2021,
PCT Pub. No. WO2020/176478, PCT Pub. Date Sep. 3, 2020.
Claims priority of provisional application 62/809,988, filed on Feb. 25, 2019.
Prior Publication US 2022/0118089 A1, Apr. 21, 2022
Int. Cl. A61K 38/20 (2006.01); A61K 38/17 (2006.01); A61K 38/18 (2006.01); A61K 38/19 (2006.01); A61K 38/21 (2006.01); A61K 39/44 (2006.01); A61K 47/64 (2017.01); A61P 37/06 (2006.01)
CPC A61K 39/44 (2013.01) [A61K 38/1709 (2013.01); A61K 38/1774 (2013.01); A61K 38/1841 (2013.01); A61K 38/191 (2013.01); A61K 38/20 (2013.01); A61K 38/2006 (2013.01); A61K 38/2026 (2013.01); A61K 38/2033 (2013.01); A61K 38/2066 (2013.01); A61K 38/2073 (2013.01); A61K 38/215 (2013.01); A61K 47/643 (2017.08); A61P 37/06 (2018.01)] 15 Claims
 
1. A method for reducing inflammation in a subject comprising administering to the subject an effective amount of a composition comprising IL-10 linked to a peptide having at least 95% sequence identity to one of SEQ ID NOs: 3, 4, 5, 47, or 52.